- Home
- MXCT vs DIAX Comparison
MXCT vs DIAX Comparison
Compare MXCT & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- DIAX
- Stock Information
- Founded
- MXCT 1999
- DIAX 2005
- Country
- MXCT United States
- DIAX United States
- Employees
- MXCT N/A
- DIAX N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- DIAX Finance Companies
- Sector
- MXCT Health Care
- DIAX Finance
- Exchange
- MXCT Nasdaq
- DIAX Nasdaq
- Market Cap
- MXCT 534.8M
- DIAX 552.4M
- IPO Year
- MXCT 2021
- DIAX N/A
- Fundamental
- Price
- MXCT $5.05
- DIAX $15.56
- Analyst Decision
- MXCT Strong Buy
- DIAX
- Analyst Count
- MXCT 2
- DIAX 0
- Target Price
- MXCT $9.50
- DIAX N/A
- AVG Volume (30 Days)
- MXCT 565.6K
- DIAX 96.6K
- Earning Date
- MXCT 03-11-2025
- DIAX 01-01-0001
- Dividend Yield
- MXCT N/A
- DIAX 7.93%
- EPS Growth
- MXCT N/A
- DIAX N/A
- EPS
- MXCT N/A
- DIAX N/A
- Revenue
- MXCT $45,599,000.00
- DIAX N/A
- Revenue This Year
- MXCT N/A
- DIAX N/A
- Revenue Next Year
- MXCT $21.13
- DIAX N/A
- P/E Ratio
- MXCT N/A
- DIAX N/A
- Revenue Growth
- MXCT 19.85
- DIAX N/A
- 52 Week Low
- MXCT $3.17
- DIAX $12.80
- 52 Week High
- MXCT $5.29
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- MXCT 66.94
- DIAX 64.28
- Support Level
- MXCT $4.64
- DIAX $14.66
- Resistance Level
- MXCT $5.20
- DIAX $15.17
- Average True Range (ATR)
- MXCT 0.30
- DIAX 0.18
- MACD
- MXCT 0.05
- DIAX 0.08
- Stochastic Oscillator
- MXCT 88.19
- DIAX 96.01
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.